ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.48) by 31.25 percent. This is a 36.96 percent decrease over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $33.658 million which beat the analyst consensus estimate of $31.321 million by 7.46 percent. This is a 114.15 percent increase over sales of $15.717 million the same period last year.